The GRHPR Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, with targeted disruption of the GRHPR gene. GRHPR encodes glyoxylate/hydroxypyruvate reductase, a critical enzyme for glyoxylate detoxification. This polyclonal format provides a heterogeneous knockout model, avoiding clonal selection artifacts and enabling study of gene disruption effects across a diverse cellular context. Researchers can employ this population for functional screening and metabolic analyses without the constraints of single-cell clones.
HeLa cells are an immortalized human cervical adenocarcinoma epithelial line with integrated HPV18 DNA, resulting in functional inactivation of the p53 and pRb tumor suppressors. This widely used cell line is highly proliferative and serves as a standard model in cancer biology, virology, and drug discovery. The compromised DNA damage response and cell cycle checkpoints create a distinctive backdrop for interrogating metabolic gene functions, particularly those related to redox balance and detoxification pathways.
The GRHPR enzyme catalyzes the NADPH-dependent reduction of glyoxylate to glycolate and hydroxypyruvate to D-glycerate, a central step in preventing toxic glyoxylate accumulation and subsequent oxalate formation. This reaction draws NADPH from the pentose phosphate pathway and intersects with glycine, serine, and threonine metabolism. Transcription factors HNF4A and PPARA regulate GRHPR expression upstream, while the enzyme cooperates with other pathway components such as AGXT, GO, HOGA1, and LDHA to maintain oxalate homeostasis. Disruption of GRHPR in this model abolishes NADPH-dependent glyoxylate reduction, leading to elevated oxalate precursors and metabolic stress.
In the HeLa context, GRHPR knockout introduces a specific metabolic vulnerability. Cancer cells with high proliferative demand often rely on altered central carbon metabolism and redox regulation. Loss of GRHPR-mediated detoxification exacerbates glyoxylate-induced cytotoxicity, offering a platform to study metabolic liabilities in p53/pRb-deficient tumors. This model also recapitulates features of primary hyperoxaluria type 2 (PH2), enabling investigation of oxalate precursor accumulation and its impact on cellular physiology beyond the canonical renal setting.
Typical applications include screening for PH2 therapeutic agents, assessing glyoxylate-induced cell death pathways, and exploring metabolic weaknesses in cervical adenocarcinoma. Researchers can validate knockout by Western blotting and RT-qPCR, measure glycolate and oxalate via LC-MS, conduct enzymatic activity assays, and perform cell viability tests under glyoxylate challenge. NADPH/NADP+ ratio analysis and immunofluorescence further characterize metabolic and subcellular consequences. For further information, please contact Ascent Research.
